<SEC-DOCUMENT>0001564590-17-013605.txt : 20170719
<SEC-HEADER>0001564590-17-013605.hdr.sgml : 20170719
<ACCEPTANCE-DATETIME>20170719090023
ACCESSION NUMBER:		0001564590-17-013605
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20170717
ITEM INFORMATION:		Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20170719
DATE AS OF CHANGE:		20170719

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			iRhythm Technologies, Inc.
		CENTRAL INDEX KEY:			0001388658
		STANDARD INDUSTRIAL CLASSIFICATION:	SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
		IRS NUMBER:				208149544
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-37918
		FILM NUMBER:		17970886

	BUSINESS ADDRESS:	
		STREET 1:		650 TOWNSEND STREET
		STREET 2:		SUITE 380
		CITY:			San Francisco
		STATE:			CA
		ZIP:			94103
		BUSINESS PHONE:		415-632-5700

	MAIL ADDRESS:	
		STREET 1:		650 TOWNSEND STREET
		STREET 2:		SUITE 380
		CITY:			San Francisco
		STATE:			CA
		ZIP:			94103

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IRhythm Technologies, Inc.
		DATE OF NAME CHANGE:	20110429

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	IRhythm Technologies Inc
		DATE OF NAME CHANGE:	20070201
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>irtc-8k_20170717.htm
<DESCRIPTION>8-K
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irtc-8k_20170717.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="border-top:Double 3pt;padding-top:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:18pt;font-weight:bold;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">UNITED STATES</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SECURITIES AND EXCHANGE COMMISSION</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Washington, D.C. 20549</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">FORM 8&#8209;K</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">CURRENT REPORT</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Pursuant to Section 13 or 15(d) of</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;letter-spacing:-0.1pt;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">The Securities Exchange Act of 1934</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date of Report (Date of earliest event reported): </p>
<p style="margin-top:12pt;text-align:center;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">July 17, 2017</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:18pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies, Inc.</p>
<p style="text-align:center;margin-bottom:12pt;margin-top:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Exact name of registrant as specified in its charter)</p>
<div>
<table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top"  style="width:29.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Delaware</p></td>
<td valign="bottom"  style="width:3.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">001-37918</p></td>
<td valign="bottom"  style="width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">20-8149544</p></td>
</tr>
<tr>
<td valign="top"  style="width:29.44%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(State or other jurisdiction of incorporation)</p></td>
<td valign="bottom"  style="width:3.74%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:31.78%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Commission File Number)</p></td>
<td valign="bottom"  style="width:2.5%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:32.54%;">
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(IRS Employer<br />Identification No.)</p></td>
</tr>
</table></div>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">650 Townsend Street, Suite 500</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">San Francisco, California 94103 </p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> <font style="font-weight:normal;">(Address of principal executive offices, including zip code)</font></p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(650) 241-7900</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Registrant&#8217;s telephone number, including area code)</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(Former name or former address, if changed since last report)</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):</p>
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:2.64%;text-indent:-2.64%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</p>
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:2.64%;text-indent:-2.64%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</p>
<p style="margin-bottom:5pt;margin-top:5pt;margin-left:2.64%;text-indent:-2.64%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.64%;text-indent:-2.64%;letter-spacing:0pt;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">[&nbsp;&nbsp;] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:2.64%;text-indent:-2.64%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (17 CFR &#167;230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR &#167;240.12b-2). </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Emerging growth company <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. <font style="font-family:'Times New Roman';"><font style="font-size:10pt;font-family:'Times New Roman'">&#9746;</font></font></p>
<p style="border-bottom:Double 3pt;padding-bottom:0pt;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;5.02 </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Departure of Directors or Certain Officers; Election of Directors; Appointment of </font><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Certain Officers; Compensatory Arrangements of Certain Officers.</font></p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">(d) Election of Director; Appointment of Committee Members</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.89%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On July 17, 2017, the Board of Directors (the &#8220;Board&#8221;) of iRhythm Technologies, Inc. (the &#8220;Company&#8221;) elected Bruce G. Bodaken and Ralph Snyderman to the Board, effective immediately. Dr. Snyderman and Mr. Bodaken will serve in the class of directors whose term expires at the annual meeting of stockholders to be held in 2019. In addition, the Board appointed Mr. Bodaken as a Chairman of the Compensation Committee of the Board and Dr. Snyderman as a member of the Audit Committee of the Board, effective July 17, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.89%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Bodaken, age 65, is a member of the faculty at University of California, Berkeley, in the Division of Health Policy Management. Mr. Bodaken served as Chairman and CEO of Blue Shield of California from 2000 to 2012, where he was responsible for strategy and management of California&#8217;s third largest insurer, with $10 billion in revenue. Prior to that, Mr. Bodaken served as Blue Shield of California&#8217;s President and COO from 1996 to 2000. He has been on the board of directors of Rite Aid Corporation since May 2013 and on the board of directors of Wageworks, Inc. since September 2005. Mr. Bodaken holds a M.A. from the University of Colorado and a B.A. from Colorado State University.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.89%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Snyderman, M.D., age 77, is Chancellor Emeritus, James B. Duke Professor of Medicine, and Director of the Center for Research on Personalized Health Care at Duke University. From 1989 to 2004, he served as Chancellor for Health Affairs at Duke and was the founding CEO and President of the Duke University Health System. He was a venture partner with New Enterprise Associates from 2006 to 2009. He previously served on the boards of directors of The Procter and Gamble Company, Pharmaceutical Product Development, LLC (PPD), Trevena, Inc., Crescendo Bioscience, Inc. and Targacept, Inc. He currently serves on the boards of CareDx, Inc., Liquida Technologies, Inc., Purdue Pharma L.P., Sengenix, Inc., Linus Oncology, Inc., Veritas Collaborative Holdings, and Essential Health Solutions, Inc. Dr. Snyderman is a member of the Association of American Physicians, where he served as president from 2003 to 2004, the Association of American Medical Colleges, where he served as chair from 2001 to 2002, the National Academy of Medicine and the American Academy of Arts &amp; Sciences. Dr. Snyderman holds a B.S. in Pre-Medical Studies from Washington College, an M.D. from the State University of New York, Downstate Medical Center, and completed an internship and residency in Medicine at Duke University. </p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.89%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.89%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In connection with the election of Dr. Snyderman and Mr. Bodaken to the Board, on July 17, 2017, each of Dr. Snyderman and Mr. Bodaken was granted a stock option award to purchase 4,089 shares of the Company&#8217;s common stock and a restricted stock unit award covering 1,949 shares of the Company&#8217;s common stock. The stock option awards will vest as to 1/36th of the shares subject to the award on each monthly anniversary of the grant date, subject to the continued service of each director on the Board on each applicable vesting date. The restricted stock unit awards will vest over a three-year period with 1/3rd of the restricted stock units scheduled to vest on each of the first three anniversaries of the grant date, subject to the continued service on the Board on each applicable vesting date. The stock option awards and restricted stock unit awards are each subject to the terms and conditions of the Company&#8217;s 2016 Equity Incentive Plan and its related grant agreements. As a director, each of Dr. Snyderman and Mr. Bodaken will participate in the compensation program applicable to all non-employee directors, which is described under the heading &#8220;Director Compensation&#8221; in the Company&#8217;s Definitive Proxy Statement relating to the Annual Meeting of Stockholders filed with the Securities and Exchange Commission on April 27, 2017.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.89%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Dr. Snyderman and Mr. Bodaken also executed the Company&#8217;s standard form of indemnification agreement, a copy of which has been filed as Exhibit 10.1 to the Company&#8217;s Registration Statement on Form S-1 (File No. 333-213773) filed with the Securities and Exchange Commission on September 23, 2016.</p>
<p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;text-indent:7.89%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There are no arrangements or understandings between Dr. Snyderman and Mr. Bodaken and any other persons pursuant to which Dr. Snyderman and Mr. Bodaken were elected as directors.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:7.89%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU3"></a>On July 19, 2017, the Company issued a press release announcing appointment of Dr. Snyderman and </p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Bodaken to the Board</font><font style="font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> as directors. The press release is attached hereto as Exhibit 99.1.</font></p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:17.78%;"></td>
<td style="width:84.59%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
</table></div>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0"  style="border-collapse:collapse; width:100%;">
<tr>
<td valign="top" style="width:15.77%;white-space:nowrap">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Item&#160;9.01</font></p></td>
<td valign="top">
<p style="margin-bottom:0pt;margin-top:0pt;font-weight:bold;font-style:normal;text-transform:none;font-variant: normal;font-family:Times New Roman;font-size:10pt;">Financial Statements and Exhibits.</p></td></tr></table></div>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:15.77%;text-indent:-15.77%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#000000;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">(d) Exhibits.</p>
<p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:17.78%;"></td>
<td style="width:84.59%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press Release issued by iRhythm Technologies, Inc. dated July 19, 2017.</p></td>
</tr>
</table></div>
<p style="text-align:justify;margin-top:9pt;margin-bottom:0pt;margin-right:4.38%;text-indent:7.89%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU4"></a><font style="font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">SIGNATURES</font></p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;text-indent:7.89%;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.</p>
<p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:10pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:104.1%;">
<tr>
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">IRHYTHM TECHNOLOGIES, INC.</p></td>
</tr>
<tr style="height:7.2pt;">
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.16%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
</tr>
<tr>
<td valign="top"  style="width:3.7%; border-bottom:solid 0.75pt transparent;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.16%; border-bottom:solid 0.75pt transparent;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.16%; border-bottom:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0.85pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">By:/s/ Kevin M. King</p></td>
</tr>
<tr style="height:23.85pt;">
<td valign="top"  style="width:3.7%;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:46.16%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;">&nbsp;</p></td>
<td valign="top"  style="width:50.16%; border-top:solid 0.75pt #000000;">
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.85pt;;text-indent:0pt;;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kevin M. King</p>
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:18.85pt;;text-indent:0pt;;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">President, Chief Executive Officer and Director</p></td>
</tr>
</table></div>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:10pt;letter-spacing:-0.1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Date:&nbsp;&nbsp;July 19, 2017</p>
<p style="margin-bottom:10pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><br /></p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<hr style="page-break-after:always;width:100%;">
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU5"></a><font style="font-weight:bold;font-size:12pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">EXHIBIT INDEX</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<div align="left">
<table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:auto;">
<tr>
<td style="width:17.78%;"></td>
<td style="width:84.59%;"></td>
</tr>
<tr>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exhibit No.</p></td>
<td valign="top" >
<p style="border-bottom:Solid 0.75pt;padding-bottom:1pt;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Description</p></td>
</tr>
<tr style="height:4pt;">
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.1</p></td>
<td valign="top" >
<p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Press Release of iRhythm Technologies, Inc. dated as of July 19, 2017.</p></td>
</tr>
</table></div>
<p style="text-align:left;margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-size:11pt;font-family:Times New Roman;font-weight:bold;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p>
<p style="margin-top:12pt;margin-bottom:0pt;text-indent:0%;font-family:Times New Roman;font-size:11pt;">&nbsp;</p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>irtc-ex991_15.htm
<DESCRIPTION>EX-99.1
<TEXT>
<!DOCTYPE HTML PUBLIC "-//W3C//DTD HTML 4.01 Transitional//EN" "http://www.w3.org/TR/html4/loose.dtd">
<html>
<head>
<title>
irtc-ex991_15.htm
</title>
</head>
<!-- NG Converter v4.0.8.13 -->
<body>

<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201707190202583891317.jpg" title="" alt="" style="width:192px;height:70px;"></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies Names UC Berkeley Faculty Member Bruce G. Bodaken and Duke University Chancellor Emeritus Ralph Snyderman, M.D. to its Board of Directors </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">SAN FRANCISCO &#8211; July 19, 2017 &#8211;<font style="font-weight:normal;"> iRhythm Technologies, Inc.&#160;(NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, announced today the appointment of Bruce G. Bodaken, member of the faculty at University of California, Berkeley in the Division of Health Policy Management, and Ralph Snyderman, M.D., Chancellor Emeritus and James B. Duke Professor of Medicine at Duke University to its Board of Directors. Mr. Bodaken will chair the compensation committee and Dr Snyderman will serve as a member of the company&#8217;s audit committee.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">&#8220;We look forward to the significant contributions that our new Board members will make,&#8221; said Kevin King, President and CEO of iRhythm Technologies. &#8220;As our healthcare system rapidly evolves, both our customers and iRhythm must be mindful of the critical balance which must be struck between business and clinical decision-making to optimize patient care. Mr. Bodaken and Dr.<font style="font-family:Times New Roman;"> </font>Snyderman will be instrumental in helping to understand and guide us through that interplay, drawing from their strong respective experiences as leaders in the healthcare payer and clinical practice fields. Their skills and backgrounds will be complementary to the strong operational and financial skills possessed by our existing board members, making for a strong group with a unique diversity of talent.&#8221;&nbsp;&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Mr. Bodaken has a proven track record of thought leadership in the healthcare payer space. Prior to joining the faculty at UC Berkeley, he was Chairman and CEO of Blue Cross Blue Shield of California from 2000 to 2012 where he was responsible for strategy and management of California&#8217;s third largest insurer. He previously served as Blue Shield of California&#8217;s President and Chief Operating Officer from 1996 to 2000. Mr. Bodaken serves on the Board of Directors of the Rite Aid Corporation and on the Board of Directors of Wageworks, Inc. Mr. Bodaken earned a master&#8217;s degree from the University of Colorado and a bachelor&#8217;s degree from Colorado State University.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><a name="_AEIOULastRenderedPageBreakAEIOU2"></a>Dr. Snyderman has made significant contributions to the advancement of health care over the course of his career. Dr. Snyderman is Chancellor Emeritus, James B. Duke Professor of Medicine, and Director of the Center for Research on Personalized Health Care at Duke University. From 1989 to 2004, he served as Chancellor for Health Affairs at Duke and was the founding CEO and President of the Duke University Health System. He was a venture partner with New Enterprise Associates from 2006 to 2009. Dr. Snyderman currently serves on a variety of health care related boards. He is a member of the Association of American Physicians, where he served as president from 2003 to 2004, the Association of American Medical Colleges, where he served as chair from 2001 to 2002, the National Academy of Medicine, and the American Academy of </p>
<p style="text-align:center;margin-top:12pt;border-top:Solid 0.75pt #0093B2;padding-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies, Inc<font style="font-weight:normal;">.&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;650 Townsend Street, Suite 500&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;San Francisco, CA&nbsp;&nbsp;94103</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">phone: 415.632.5700&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;fax: 415.632.5701&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:none;color:#31849B;">irhythmtech.com</font></p>
<hr style="page-break-after:always;width:100%;">
<p style="text-align:right;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><img src="g201707190202583891317.jpg" title="" alt="" style="width:192px;height:70px;"></p>
<p style="margin-bottom:0pt;margin-top:0pt;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"><font style="font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Arts &amp; Sciences. Dr. Snyderman earned a bachelor&#8217;s degree from Washington College, a doctorate of medicine from the State University of New York, Downstate Medical Center, and completed his internship and residency in Medicine</font><font style="font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> at Duke University.</font></p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-weight:bold;;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;color:#auto;font-family:Arial;font-size:12pt;font-style:normal;text-transform:none;font-variant: normal;">About iRhythm Technologies, Inc. </p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Arial;font-size:12pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Investor Relations Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lynn Pieper Lewis or Leigh Salvo</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(415) 937-5404</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">investors@irhythmtech.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-weight:bold;font-size:12pt;font-family:Arial;font-style:normal;text-transform:none;font-variant: normal;">Media Contact:</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Aaron Murphy&#160;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(415) 229-3331</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:12pt;font-family:Arial;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">media@irhythmtech.com</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;">&nbsp;</p>
<p style="margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-family:Times New Roman;font-size:12pt;">&nbsp;</p>
<p style="text-align:center;margin-top:12pt;border-top:Solid 0.75pt #0093B2;padding-top:8pt;margin-bottom:0pt;text-indent:0%;font-weight:bold;font-size:9pt;font-family:Calibri;font-style:normal;text-transform:none;font-variant: normal;">iRhythm Technologies, Inc<font style="font-weight:normal;">.&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;650 Townsend Street, Suite 500&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;San Francisco, CA&nbsp;&nbsp;94103</font></p>
<p style="text-align:center;margin-bottom:0pt;margin-top:0pt;text-indent:0%;font-size:9pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">phone: 415.632.5700&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp;fax: 415.632.5701&nbsp;&nbsp;&nbsp;&nbsp;&#8226;&nbsp;&nbsp;&nbsp;&nbsp; <font style="font-weight:bold;text-decoration:none;color:#31849B;">irhythmtech.com</font></p></body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g201707190202583891317.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g201707190202583891317.jpg
M_]C_X  02D9)1@ ! 0$ E@"6  #_[@ .061O8F4 9      !_^$.?D5X:68
M $U- "H    (  <!$@ #     0 !   !&@ %     0   &(!&P %     0
M &H!*  #     0 "   !,0 "    )    '(!,@ "    %    ):':0 $
M 0   *H   #* )8    !    E@    $  $%D;V)E(%!H;W1O<VAO<"!#0R R
M,#$U("A-86-I;G1O<V@I #(P,3<Z,#$Z,3 @,30Z,3(Z,38   *@ @ $
M 0   2R@ P $     0   &X         !@$#  ,    !  8   $:  4    !
M   !& $;  4    !   !( $H  ,    !  (   (!  0    !   !* ("  0
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M!0$! 0$! 0         #  $"! 4&!P@)"@L!  $% 0$! 0$!          $
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M[M#=NUW]9^4QW_6UM?XJ^G?8?J;BO+2VS-?9E6 _RCZ51'];'II<M7K?U/\
MJ[U^^O(ZOBG)MI9Z=9]6U@#9W?0HMJ9](K4Q,6C#Q:<3&;Z>/CUMJI9).UC
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M=')21T(@6%E:( ?.  ( "0 & #$  &%C<W!-4T94     $E%0R!S4D="
M           !  #VU@ !     -,M2% @(
M                                    $6-P<G0   %0    ,V1E<V,
M  &$    ;'=T<'0   'P    %&)K<'0   ($    %')865H   (8    %&=8
M65H   (L    %&)865H   )     %&1M;F0   )4    <&1M9&0   +$
MB'9U960   -,    AG9I97<   /4    )&QU;6D   /X    %&UE87,   0,
M    )'1E8V@   0P    #')44D,   0\   (#&=44D,   0\   (#&)44D,
M  0\   (#'1E>'0     0V]P>7)I9VAT("AC*2 Q.3DX($AE=VQE='0M4&%C
M:V%R9"!#;VUP86YY  !D97-C         !)S4D="($E%0S8Q.38V+3(N,0
M            $G-21T(@245#-C$Y-C8M,BXQ
M                                          !865H@        \U$
M 0    $6S%A96B                      6%E:(        &^B   X]0
M Y!865H@        8ID  +>%   8VEA96B         DH   #X0  +;/9&5S
M8P         6245#(&AT=' Z+R]W=W<N:65C+F-H               6245#
M(&AT=' Z+R]W=W<N:65C+F-H
M                         &1E<V,         +DE%0R V,3DV-BTR+C$@
M1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@              +DE%
M0R V,3DV-BTR+C$@1&5F875L="!21T(@8V]L;W5R('-P86-E("T@<U)'0@
M                          !D97-C         "Q2969E<F5N8V4@5FEE
M=VEN9R!#;VYD:71I;VX@:6X@245#-C$Y-C8M,BXQ               L4F5F
M97)E;F-E(%9I97=I;F<@0V]N9&ET:6]N(&EN($E%0S8Q.38V+3(N,0
M                            =FEE=P      $Z3^ !1?+@ 0SQ0  ^W,
M  03"P #7)X    !6%E:(       3 E6 %    !7'^=M96%S          $
M                       "CP    )S:6<@     $-25"!C=7)V
M!      %  H #P 4 !D '@ C "@ +0 R #< .P!  $4 2@!/ %0 60!> &,
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MJ*FJM+6VM[BYNL3%QL?(R<K4U=;7V-G:Y.7FY^CIZO3U]O?X^?K_Q  ? 0
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M]B]6[^W=@Z*FI16SU68V[M7*Y;&0I2&.5:C76TB J48$7N"./9SR[80[IO\
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MZ?8(TK_INA)_>#\T^#L7M]R7%)FXNIKR0>@@00PU^3&XFI\T^SH /Y 75_\
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M+.SK$@<K&I8LSTU$T%22>N FX\\^Y?NGOUEM&\\W[E?7.XWB11PR7$S0AYY
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MN!XBI6&,2(3)\)J:$Z6H(/\ I V;_H__ -*?\?H_]'W]SO\ 2!_>C34?P_\
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M>&\=OSPIM//9WJ+?NX-RX2I-0):=-NY3(=55>4QLYJWU(*:1&\AN/5[>^GN
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MQLM)IXS.WS\9BZ'_ )QE!^77"K[UG-/]:_??GN>.35:V4ZV48XZ?I$6*4?\
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MI!G(-.C3N?(8R',;J?1]5\NY,C5/8\^KGGWSYYTW;]^<V<P[J&U1S7<A0_\
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MR-]X;=OI.4MOVI&I)>78)'K'"I9OV.8NL?ON$\K?O7W2WWF>6.MOM.UL%/\
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M%131WGGJ,SO#/U>5DIXK"\LLE;D2B_U)'OI+M]I!LVU6-@C 6UK;I&#P 6-
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MP/7RV_\ H'%_G7?]X&;_ /\ T8'2/_VS_9K]3!_OS_#U2A].OJ@?RTOC1/\
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H]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=>]^Z]U[W[KW7O?NO=?_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
